CDK4 and neoplasm: recently reported that tumor growth in the 4T1 model could be abrogated by promoting a hotter TIME when blocking Tyro3, Axl, MerTK, and Met with the small molecule inhibitor sitravatinib and that this blockade enhances the anti-tumor effect of CDK4/6 inhibition (45).